logo Creation made simple
Beautifully designed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut convallis tempor orci vitae vehicula. Aliquam in ullamcorper lacus.
Follow & share
Search:
Infallible Pharma | THROFIN INJECTION
21166
portfolio_page-template-default,single,single-portfolio_page,postid-21166,edgt-core-1.0.1,ajax_fade,page_not_loaded,,hudson-ver-1.8, vertical_menu_with_scroll,smooth_scroll,side_menu_slide_from_right,blog_installed,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

THROFIN INJECTION

THROFIN INJECTION


Brand Name : Throfin


Generic Name : Clarithromycin Injection BP 500 mg


Pack Size : Vial + WFI


Dosage Form : Powder for Injection


Strength : 500 mg


Therapeutic indications : Clarithromycin 500 mg Powder for Solution for Infusion is indicated in adults and children aged 12 years and over.
Clarithromycin 500 mg Powder for Solution for Infusion is indicated whenever parenteral therapy is required for treatment of infections caused by susceptible organisms in the following conditions:
– Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia.
– Upper respiratory tract infections for example, sinusitis and pharyngitis.
– Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.


Pharmacotherapeutic group : Antibacterial for systemic use, macrolide


ATC code : J01FA09


Pharmacodynamic properties : Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria.
The 14-hydroxy metabolite of clarithromycin, a product of parent drug metabolism also has anti-microbial activity. The metabolite is less active than the parent compound for most organisms, including mycobacterium spp. An exception is Haemophilus influenza where the 14-hydroxy metabolite is two-fold more active than the parent compound.

Date

February 18, 2022

Share